Drug for common bowel disorder
People who take a commonly-prescribed drug for inflammatory bowel disease (IBD) should not assume they are protected after a first dose of Covid-19 vaccine, say the authors of a large-scale study that found many had poor antibody responses.
Daily Current Affairs Quiz 2021
The research measured antibody responses after vaccination with the Pfizer-BioNTech or the Oxford-AstraZeneca Covid-19 vaccine in 865 people treated with infliximab, an anti-tumour necrosis factor (anti-TNF) biologic drug, prescribed to around two million people worldwide.
One of the brand names under which infliximab is marketed is Remicade, which has got regulatory clearance in India.
Anti-TNF drugs are effective treatments for immune-mediated inflammatory diseases, but by suppressing the immune system, they can reduce vaccine effectiveness and increase risk of serious infection, the researchers have suggested.
Take Mock Tests
Government Schemes Mock Test | Start Test! |
Political Science Mock Test – 42 | Start Test |
History Test – 190 | Start Test |
Quantitative Aptitude Test | Start Test! | Data Interpretation - Mock Test | Start Test! |
General Awareness - Mock Test | Start Test! |
Reasoning Ability - Mock Test | Start Test! |